The role of interleukin-22 in lung health and its therapeutic potential for COVID-19

Although numerous clinical trials have been implemented, an absolutely effective treatment against coronavirus disease 2019 (COVID-19) is still elusive. Interleukin-22 (IL-22) has attracted great interest over recent years, making it one of the best-studied cytokines of the interleukin-10 (IL-10) fa...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 13; p. 951107
Main Authors Fang, Si, Ju, Dianwen, Lin, Yong, Chen, Wei
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 27.07.2022
Subjects
COVID-19
COVID-19 - immunology
COVID-19 Drug Treatment
Cytokines - immunology
Cytokines - therapeutic use
Humans
Immunology
immunotherapeutic strategy
Interleukin-22
Interleukins - immunology
Interleukins - therapeutic use
lung
Lung - immunology
SARS-CoV-2 infection
COVID-19
lung
SARS-CoV-2 infection
interleukin-22
immunotherapeutic strategy
Online AccessGet full text

Cover

More Information
Summary:Although numerous clinical trials have been implemented, an absolutely effective treatment against coronavirus disease 2019 (COVID-19) is still elusive. Interleukin-22 (IL-22) has attracted great interest over recent years, making it one of the best-studied cytokines of the interleukin-10 (IL-10) family. Unlike most interleukins, the major impact of IL-22 is exclusively on fibroblasts and epithelial cells due to the restricted expression of receptor. Numerous studies have suggested that IL-22 plays a crucial role in anti-viral infections through significantly ameliorating the immune cell-mediated inflammatory responses, and reducing tissue injury as well as further promoting epithelial repair and regeneration. Herein, we pay special attention to the role of IL-22 in the lungs. We summarize the latest progress in our understanding of IL-22 in lung health and disease and further discuss maneuvering this cytokine as potential immunotherapeutic strategy for the effective manage of COVID-19.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Hui-Rong Jiang, University of Strathclyde, United Kingdom
This article was submitted to Cytokines and Soluble Mediators in Immunity, a section of the journal Frontiers in Immunology
Reviewed by: Hussein Kadhem Al-Hakeim, University of Kufa, Iraq; Harapan Harapan, Syiah Kuala University, Indonesia
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.951107